REG - Novacyt S.A. - Notice of rescheduled AGM

Novacyt SAAnnouncement

05/10/2023 14:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231005:nRSE8669Oa&default-theme=true

RNS Number : 8669O  Novacyt S.A.  05 October 2023

 

Novacyt S.A.

("Novacyt", the "Company" or the "Group")

 

Notice of rescheduled AGM

 

AGM to be held in Paris on Thursday 26 October

 

Paris, France and Eastleigh, UK - 05 October 2023 - Novacyt (EURONEXT GROWTH:
ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,
announces that the Company's Annual General Meeting (AGM), due to take place
earlier today, will be rescheduled and held in person in Paris on Thursday 26
October at 1pm BST/2pm CEST.

 

To function as a procedural meeting, the AGM requires a sufficient number of
shareholder votes to constitute a quorum to ensure the AGM is validly held in
accordance with French corporate law. This threshold has not been met,
therefore, in accordance with Article 19 of Novacyt articles of association,
the AGM has been rescheduled.

 

The rescheduled AGM will be an open meeting exclusively, held in The Hilton
Hotel, Paris Charles De Gaulle Airport, and will also be streamed online for
those shareholders wishing to join virtually. Online votes will not be open.
The agenda will remain the same as in the first convening and the AGM will
comprise of both ordinary and extraordinary resolutions.

 

Shareholders can register to view the AGM via the online meeting platform by
visiting https://novacytagm23.eventcaster.co.uk
(http://www.novacytagm23.eventcaster.co.uk) .

 

Forms of Proxy already completed and submitted and votes cast by electronic
means for the first AGM remain valid for all meetings subsequently convened
with the same agenda (art. R. 225-77 of the French commercial code). Further
information on voting procedures and deadlines will follow in due course.

 

Contacts

 

 Novacyt SA                                                +44 (0)23 8074 8830
 James Wakefield, Non-Executive Chairman

 James McCarthy, Acting Chief Executive Officer

 SP Angel Corporate Finance LLP (Nominated Adviser and Broker)                           +44 (0)20 3470 0470

 Matthew Johnson / Charlie Bouverat (Corporate Finance)

 Vadim Alexandre / Rob Rees (Corporate Broking)

 Numis (Joint Broker)                                                                    +44 (0)20 7260 1000
 Freddie Barnfield / Duncan Monteith / Jack McLaren

 Allegra Finance (French Listing Sponsor)                                                 +33 (1) 42 22 10 10

                                                                                       r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
 Rémi Durgetto / Yannick Petit                                                           y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 Walbrook PR (Financial PR & IR)                           +44 (0)20 7933 8780

 Stephanie Cuthbert / Anna Dunphy / Phillip Marriage       novacyt@walbrookpr.com (mailto:novacyt@walbrookpr.com)

 

About Novacyt Group

Novacyt is an international diagnostics business delivering a broad portfolio
of in vitro and molecular diagnostic tests for a wide range of infectious
diseases, enabling faster, more accurate, accessible testing to improve
healthcare outcomes. The Company provides customers with a seamless
sample-to-result workflow using its integrated and scalable
instrumentation/solutions. The Company specialises in the design, manufacture,
and supply of real-time PCR kits, reagents and a full range of laboratory and
qPCR instrumentation for molecular biology research and clinical use. Novacyt
offers one of the world's most varied and comprehensive range of qPCR assays,
covering human, veterinary, biodefence, environmental, agriculture and food
testing.

 

The acquisition of Yourgene in September 2023 added a complementary
international genomics technology and services business, focussed on
delivering accurate molecular diagnostic and screening solutions, across
reproductive health and precision medicine. Yourgene's portfolio of in vitro
diagnostic products includes non-invasive prenatal tests (NIPT) for Down's
Syndrome and other genetic disorders, Cystic Fibrosis screening tests,
invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene also
works in partnership with global leaders in DNA technology to allow its
Ranger® Technology to deliver dynamic target enrichment.

 

Novacyt is headquartered in Vélizy in France with offices in the UK in
Stokesley, Eastleigh and Manchester. The Company also has offices in Taipei
(divestment pending), Singapore, the US and Canada and is listed on the London
Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext
Growth ("ALNOV").

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFZMGGZKKGFZM